On June 29, Sino Biopharmaceutical rose 3.05% in regular trading, trading at HK$4.5/share, with turnover of HK$122 million. The stock rebounded from its recent 52-week low near HK$4.37, supported by a broad pharmaceuticals sector rally and multiple company-specific catalysts.

The company recently announced a share buyback plan of up to HK$2 billion over the next 12 months, with the board explicitly stating it believes the company is severely undervalued. On June 25, the company repurchased 11.553 million shares for approximately HK$49.1 million. Additionally, key pipeline milestones have accumulated, including NMPA acceptance of the new drug application for tecotabart vedotin (LM-302) for gastric cancer, and marketing approval for Peceleganan Spray for wound infections.

Within the Pharmaceuticals sector, the overall performance was strongly positive. Among individual stocks, ASYMCHEM up 7.37%, CSPC PHARMA up 6.73%, LUYE PHARMA up 5.06%, HENGRUI PHARMA up 4.91%, HANSOH PHARMA up 3.42%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)